Discover
NTLA
Intellia Therapeutics, Inc.
13.63
22 x 13.58
8 x 13.77
bid
ask
-
2.24
14.11%
15 @ 08:55 AM
14.22 +0.59 (4.33%)
| Ytd | 51.61% | |
| 1y | 66.63% |
13.42
day range
16.04
6.83
52 week range
28.25
| Open | 15.89 | Prev Close | 15.87 | Low | 13.42 | High | 16.04 | Mkt Cap | 1.61B |
| Vol | 9.03M | Avg Vol | 3.82M | EPS | -3.81 | P/E | N/A | Forward P/E | -5.43 |
| Beta | 1.99 | Short Ratio | 8.95 | Inst. Own | 85.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 13.54 | 200-d Avg | 13.13 | 1yr Est | 25.29 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-14 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-02-26 | 2025-12 | 0 | N/A | 0.16 | 16.16% |
| 2025-11-06 | 2025-09 | 0 | N/A | 0.1 | 9.80% |
| 2025-08-07 | 2025-06 | 0 | N/A | 0.04 | 3.88% |
| 2025-05-08 | 2025-03 | 0 | N/A | 0.16 | 12.70% |
| 2025-02-27 | 2024-12 | 0 | N/A | 0.08 | 6.06% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-03-04 | Jones Trading | Upgrade | Hold | Buy |
| 2026-03-03 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-03-03 | Leerink Partners | Upgrade | Outperform | Outperform |
| 2026-03-03 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
| 2026-03-03 | Wells Fargo | Upgrade | Equal-Weight | Equal-Weight |
| 2026-03-03 | Citizens | Upgrade | Market Outperform | Market Outperform |
Profile
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-03-01 | BASTA JAMES EDMUND | General Counsel | 156.79K | Sale |
| 2025-08-19 | CHASE WILLIAM J | Director | 134.69K | Purchase |
| 2026-03-01 | CLARK ELIANA | Chief Technology Officer | 93.86K | Sale |
| 2026-01-04 | COHEN FREDERICK E. M.D. PH.D. | Director | 207.45K | Purchase |
| 2026-02-26 | DUBE MICHAEL P | Officer | 69.53K | Stock Award(Grant) |
| 2026-02-26 | DULAC EDWARD J III | Chief Financial Officer | 160.96K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | ARK Investment Management, LLC | 14.21M | 193.65M | 12.03% |
| 2025-12-30 | Vanguard Group Inc | 13.01M | 177.33M | 11.01% |
| 2025-12-30 | Blackrock Inc. | 10.28M | 140.07M | 8.70% |
| 2025-12-30 | State Street Corporation | 6.42M | 87.49M | 5.43% |
| 2025-12-30 | Shaw D.E. & Co., Inc. | 5.33M | 72.66M | 4.51% |
| 2025-12-30 | Regeneron Pharmaceuticals Inc | 3.70M | 50.47M | 3.13% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-02-27 | ARK ETF Trust-ARK Innovation ETF | 9.24M | 125.89M | 7.82% |
| 2026-03-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.93M | 53.53M | 3.32% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.64M | 49.60M | 3.08% |
| 2026-02-27 | ARK ETF Trust-ARK Genomic Revolution ETF | 2.91M | 39.60M | 2.46% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.63M | 35.88M | 2.23% |
| 2026-02-27 | iShares Trust-iShares Russell 2000 ETF | 2.50M | 34.02M | 2.11% |
